Lyme disease has become one of the most underreported, underrecognized, and difficult to manage infectious diseases of 21st Century.

Its name originates from the first recognized case in the small town of Lyme, Conneticut and the causative factor -a spirochete bacteria belonging to Borrelia family was discovered by Dr. Burgdorfer in 1982. The organism was subsequently named Borrelia burgdorferi.

According to the Center for Disease Control in Atlanta there are about 200 000 cases have been reported but it is estimated by many researchers the actual number of cases can be as high as ten times more than that.

Borrelia burgdorferi. is very tough bacteria, resistant to treatments and quite difficult to detect by routine laboratory testing . According to many formal and informal studies this spirochete is present in many patients suffering from many types of disorders including Chronic Fatigue Syndrome, Fibromyalgia, Systemic Lupus, Rheumatoid Arthritis, Scleroderma, other autoimmune disorders, as well as many neurological conditions including Multiple Sclerosis, Bell's Palsy, ALS , Alzheimer's Disease and more.

Lyme disease is a primarily a tick-borne disease . Because ticks can carry other infectious organism along with the Borrelia burgdorferi, many patients with Lyme's suffer from infections of Babesia, Ehrlichia, Chlamydia, Bartonella, Mycoplasma, as well as viral, fungal and parasitic organisms.

Presently the only available treatment in conventional medicine is prolonged antibiotic therapy which requires a long-term commitment and life style adjustment. (lost work, severe complications, etc.) and often yields dissapointing results.

At Manhattan Advanced Medicine we treat Lyme disease with very promising results utilizing the Biological Medicine principles of individual program treatment which in most cases require:

First Phase(3-4 weeks)

1. General detoxification
2. The strengthening of the immune system.
3. The elimination of other neurotoxins.
4. Nutritional and psycho-emotional support.

Second Phase

The administration of an intravenous antimicrobial treatment (Sulfoxime, Dioxychlor) developed by the Bradford Research Institute.

Final Phase

The final phase of therapy utilizes Intravenous Lipid Exchange in order to rebuild the cellular membranes damaged by the infectious organism and/or its related toxins.

This individualized program of treatment has yielded excellent results incuding the complete elimination of microorganism and full restoration of the patient's health.